Humacyte has been granted a patent for a system that cultivates hollow, tubular tissues using bioreactors with mandrel tubes. The system includes a fluid management system with pumps, valves, and clamps to control fluid flow. This innovation could revolutionize tissue engineering and regenerative medicine. GlobalData’s report on Humacyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Humacyte, Prosthetic cardiac valves was a key innovation area identified from patents. Humacyte's grant share as of May 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.